Mirna Therapeutics, Inc. (NASDAQ:SYBX) – Equities researchers at Wedbush issued their FY2017 earnings per share (EPS) estimates for shares of Mirna Therapeutics in a research report issued on Monday. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings of ($5.26) per share for the year. Wedbush has a “Outperform” rating and a $20.00 price target on the stock. Wedbush also issued estimates for Mirna Therapeutics’ Q4 2017 earnings at ($0.79) EPS, FY2018 earnings at ($3.35) EPS, FY2019 earnings at ($3.09) EPS, FY2020 earnings at ($2.71) EPS and FY2021 earnings at ($2.55) EPS.

Other equities research analysts have also issued research reports about the stock. Leerink Swann assumed coverage on shares of Mirna Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $25.00 price objective on the stock. Zacks Investment Research cut shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 22nd. Finally, ValuEngine cut shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Mirna Therapeutics has an average rating of “Hold” and a consensus target price of $19.67.

Shares of Mirna Therapeutics (NASDAQ SYBX) opened at $10.16 on Thursday. Mirna Therapeutics has a 12 month low of $8.76 and a 12 month high of $23.00.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/30/equities-analysts-set-expectations-for-mirna-therapeutics-inc-s-fy2017-earnings-sybx.html.

About Mirna Therapeutics

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.